SAN DIEGO, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Ann Rhoads, Chief Financial Officer will present at the Oppenheimer 24th Annual Healthcare Conference in New York on December 11, 2013.
Event: Oppenheimer 24th Annual Healthcare Conference
Date: Wednesday, December 11, 2013
Place: New York City
Time: 8:55 am ET/ 5:55 am PT
The presentation will be webcast live and archived for 30 days on Zogenix' Investor Relations website at ir.zogenix.com.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning. Zogenix recently received FDA approval for Zohydro ER (hydrocodone bitartrate) extended-release capsules, the first extended-release oral formulation of hydrocodone without acetaminophen. Zogenix developed and commercialized the first needle-free subcutaneous injection, SUMAVEL® DosePro® (sumatriptan injection) for migraine and cluster headache. The development pipeline for Zogenix includes a once-monthly subcutaneous injection for schizophrenia.
Zack Kubow | The Ruth Group
646.536.7020 | email@example.com
Amy Wheeler | The Ruth Group
646.536.7025 | firstname.lastname@example.orgZogenix